Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MTAU9937A in prodromal to mild Alzheimer's disease
NL-OMON48730Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semorinemab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (5 arms), sponsored by Genentech. Primary endpoints: Change from baseline to Week 73 on the Clinical Dementia Rating Scale Sum of Boxes, Adverse events and serious adverse events and 3 more. Started Jun 2018; status: active, not recruiting.
02
Drugs
semorinemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON48730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48730.